Search Results

Assertio Holdings, Inc. today announced that Ajay Patel, Chief Financial Officer, will present at the Alliance Global Partners Virtual Healthcare Company Showcase to be held virtually on May 21, 2024.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21.

Assertio Holdings, Inc. announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024.

Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets.

GE HealthCare, a leader in precision care innovation, will host an investor day on Thursday, November 21, 2024, in New York, NY.

Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29th.

YS Biopharma Co., Ltd., a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, announced the results of its extraordinary general meeting held on May 21, 2024 in Hong Kong.

Chromocell Therapeutics Corporation today announced that its CEO Frank Knuettel, will be presenting at Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024.

Xtant Medical Holdings, Inc. today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29 in Minneapolis.

Boston Pharmaceuticals today announced new Phase 2a data demonstrating the positive impact of BOS-580, an investigational, long-acting fibroblast growth factor 21 (FGF21) analogue, on the circulating lipidome and changes in the metabolomics advanced steatohepatitis fibrosis (MASEF) score in patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH).